VIDEO: Targeted therapy in lung cancer ‘personalized medicine at its best’
Click Here to Manage Email Alerts
In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, provided a quick rundown of presentations from the Chemotherapy Foundation Symposium that focused on targeted therapy.
According to Herbst, who also serves as ensign professor of medicine and professor of pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, experts reviewed targeted therapy options for EGFR, BRAF, MET, HER2 and KRAS mutations, and ALK, ROS1, RET and NTRK fusions.
“Truly heralding personalized medicine at its best,” he said.
References:
- Drilon AE. Targeting ALK, ROS1, RET, and NTRK Fusions. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.
- Horn L. Targeting BRAF, MET, HER2, and KRAS Mutations. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.
- Mok TS. Targeting EGFR-Mutant Lung Cancers. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.